JCO Flashback: Cisplatin Plus Gemcitabine Vs. Cisplatin Plus Pemetrexed-A Comparative Analysis (2008)

被引:0
|
作者
不详
机构
关键词
D O I
10.1200/JCO.23.00256
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
引用
收藏
页码:2457 / 2457
页数:1
相关论文
共 50 条
  • [1] Nivolumab Plus Cisplatin/Pemetrexed or Cisplatin/Gemcitabine as Induction in Resectable NSCLC
    Zinner, R.
    Cowan, S.
    Solomides, C.
    Hooper, D. C.
    Harshyne, L.
    Lu-Yao, G.
    Yang, H.
    Phan, L.
    Poller, D.
    Leiby, B.
    Werner-Wasik, M.
    Lu, B.
    Johnson, J.
    Axelrod, R.
    Argiris, A.
    Evans, N.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S1028 - S1029
  • [2] Comparison of Gemcitabine Plus Cisplatin vs. Docetaxel Plus Fluorouracil Plus Cisplatin Palliative Chemotherapy for Metastatic Nasopharyngeal Carcinoma
    Sun, Xue-Song
    Wang, Xiao-Hao
    Liu, Sai-Lan
    Luo, Dong-Hua
    Sun, Rui
    Liu, Li-Ting
    Guo, Shan-Shan
    Chen, Qiu-Yan
    Tang, Lin-Quan
    Mai, Hai-Qiang
    FRONTIERS IN ONCOLOGY, 2020, 10
  • [3] Nivolumab plus cisplatin/pemetrexed or cisplatin/gemcitabine as induction in resectable NSCLC.
    Evans, Nathaniel R.
    Cowan, Scott
    Solomides, Charalambos
    Hooper, D. Craig
    Harshyne, Larry
    Lu-Yao, Grace L.
    Yang, Hushan
    Phan, Linda
    Poller, Dawn
    Leiby, Benjamin
    Werner-Wasik, Maria
    Lu, Bo
    Johnson, Jennifer Maria
    Axelrod, Rita Susan
    Argiris, Athanassios
    Zinner, Ralph
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [4] Comparison of cisplatin plus pemetrexed and cisplatin plus gemcitabine for the treatment of malignant pleural mesothelioma in Japanese patients
    Shukuya, Takehito
    Takahashi, Toshiaki
    Imai, Hisao
    Tokito, Takaaki
    Ono, Akira
    Akamatsu, Hiroaki
    Taira, Tetsuhiko
    Kenmotsu, Hirotsugu
    Naito, Tateaki
    Murakami, Haruyasu
    Endo, Masahiro
    Yamamoto, Nobuyuki
    RESPIRATORY INVESTIGATION, 2014, 52 (02) : 101 - 106
  • [6] Neoadjuvant nivolumab (N) plus cisplatin (C)/pemetrexed (P) or cisplatin /gemcitabine (G) in resectable NSCLC.
    Zinner, Ralph
    Axelrod, Rita
    Solomides, Charalambos C.
    Cowan, Scott
    Leiby, Benjamin
    Bhatia, Avnish K.
    Sundermeyer, Mark L.
    Hooper, D. Craig
    Harshyne, Larry
    Lu-Yao, Grace L.
    Quereda-Bernabeu, Belen C.
    Whang, Sung C.
    OHara, Suzanne C.
    Vernau, Daniel C.
    Werner-Wasik, Maria
    Lu, Bo
    Johnson, Jennifer M.
    Scott, Walter C.
    Argiris, Athanassios
    Evans, Nathaniel R.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [7] Gemcitabine plus cisplatin in breast cancer
    Nagourney, RA
    ONCOLOGY-NEW YORK, 2001, 15 (02): : 28 - 33
  • [8] Randomised phase II trial of gemcitabine plus vinorelbine vs gemcitabine plus cisplatin vs gemcitabine plus capecitabine in patients with pretreated metastatic breast cancer
    Stemmler, H. J.
    diGioia, D.
    Freier, W.
    Tessen, H. W.
    Gitsch, G.
    Jonat, W.
    Brugger, W.
    Kettner, E.
    Abenhardt, W.
    Tesch, H.
    Hurtz, H. J.
    Roesel, S.
    Brudler, O.
    Heinemann, V.
    BRITISH JOURNAL OF CANCER, 2011, 104 (07) : 1071 - 1078
  • [9] Randomised phase II trial of gemcitabine plus vinorelbine vs gemcitabine plus cisplatin vs gemcitabine plus capecitabine in patients with pretreated metastatic breast cancer
    H J Stemmler
    D diGioia
    W Freier
    H W Tessen
    G Gitsch
    W Jonat
    W Brugger
    E Kettner
    W Abenhardt
    H Tesch
    H J Hurtz
    S Rösel
    O Brudler
    V Heinemann
    British Journal of Cancer, 2011, 104 : 1071 - 1078
  • [10] Efficacy and Safety of Vinorelbine Plus Cisplatin vs. Gemcitabine Plus Cisplatin for Treatment of Metastatic Triple-Negative Breast Cancer After Failure with Anthracyclines and Taxanes
    Wang, Junbin
    Zheng, Rongsheng
    Wang, Zishu
    Yang, Yan
    Wang, Mingxi
    Zou, Weiyan
    MEDICAL SCIENCE MONITOR, 2017, 23 : 4657 - 4664